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Maximal Androgen Ablation: A Review 
Brian J. Miles, MD,* and Joseph Babiarz, MD^ 
Primary management of advanced (stage D) adenocarcinoma ofthe prostate is androgen ablation. 
Since this principle was discovered in the early 1940s, therapeutic alternatives and "progress" have 
centered around different ways to obtain castrate levels of androgens. The role of adrenal androgens 
in supporting prostate or prostatic cancer growth has been debated for decades and until recently was 
believed to be minimal. In the 1980s the concept of maxinium androgen suppression, involving both 
the testes and adrenal glands, was reintroduced with some investigators claiming exceptional resulls. 
We review studies that have examined this concept, with emphasis on the largest trial which was 
carried out by the National Cancer Institute. (Henry Ford Hosp MedJ 1992:40:114-7) 
I n 1941 Huggins and Hodges (1) published their landmark paper on the effects of androgen withdrawal on advanced 
adenocarcinoma of the prostate. This early work was the first to 
establish the hormone dependency of a human cancer. Since 
then, the endocrine physiology of the prostate has been well de-
fined (Fig 1) (2). The testes, under direct control of the pituitary, 
produce testosterone, the main androgen support of the prostate. 
The remaining androgens in males are produced by the adrenal 
glands primarily as androstenedione. A total of 95% of circulat-
ing androgens are in the form of testosterone. The therapeutic 
options to ablate or suppress androgens include bilateral or-
chiectomy (castration) and administration of estrogens, luteiniz-
ing hormone-releasing hormone (LHRH) agonists, or various 
antiandrogens. 
Bilateral orchiectomy has been the mainstay of therapy for 
advanced prostate carcinoma since the time of Huggins and 
Hodges. The procedure is simple, effective, and immediate. The 
major difficulty has been the psychological effect of significant 
body image changes associated with this procedure. Estrogen 
therapy had been the main altemative to castration until the past 
tive years. 
Estrogen therapy induces a "pharmacological castration" by 
suppressing the hypothalamic-pituitary stimulation of the testis. 
A number of studies have shown that the cardiovascular side ef-
fects of estrogens in males are severe, with cardiovascular death 
occuning in up to 15% of patients (3,4). LHRH agonists have 
become the main altemative to castration because with their use 
cardiovascular toxicity is essentially zero (5). The pituitary is re-
sponsive to intermittent stimulation by LHRH from the hypo-
thalamus, but when subjected to constant stimulation by LHRH 
(or a long-acting LHRH agonist) the pituitary is desensitized 
and stops secreting luteinizing hormone (LH). Accordingly, 
LHRH agonists have the paradoxic effect of suppressing LH 
production, inducing pharmacologic castration. 
Antiandrogens have various mechanisms of action. The mo.st 
popular, flutamide, competitively inhibits the uptake of dihy-
drotestosterone (the active form of testosterone) by the prostate 
nuclear receptor (6). Because the prostate cells cannot bind 
dihydrotestosterone, DNA transcription cannot take place and 
cellular reproduction is prevented. Because the agent is a com-
petitive inhibitor, it acts to release the "balanced" levels of LH 
and serum testosterone rises. Flutamide has not been approved 
as monotherapy owing to concems that its competitive inhibit-
ing effects might be overcome by increasing testosterone. Such 
result has not yet been observed in small, nonrandomized clini-
cal trials. An advantage of flutamide as monotherapy is due to 
the fact that serum testosterone levels remain in the upper nor-
mal range and sexual libido is not impaired. 
Alt primary methods to achieve androgen deprivation in pa-
tients with advanced prostate carcinoma are equally effective as 
monotherapy, with approximately 80% objective respon.se rate 
(7). In 10% of patients the disease progresses as if they had re-
ceived no treatment, but 10% survive 10 or more years with no 
evidence of progressing disease. Generally, even in patients 
who respond, the disease progresses at a median of 18 months to 
2 years, and median survival is approximately 30 months. 
The reason patients fail androgen ablation has been the source 
of much investigation. Huggins and Scott (8) suggested that ad-
renal androgens must be supporting the prostate carcinoma and 
they attempted bilateral adrenalectomy in patients whose dis-
ease progressed after castration. Along with other investigators, 
however, they demonstrated that either hypophysectomy or 
adrenalectomy was ineffective with objective response rates of 
only 6% to 7% (7). 
Patients who fail primary ablation of testicular androgen must 
do so either because the cancer includes an androgen-indepen-
dent clone of cells or, altematively, a clone which is "supersen-
sitive" to androgen has been setected and proliferated (9). If 
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Fig 1—The mechanism of action of androgen on target tissues. 
The plasma factors affecting androgen action are shown by 
numbers ofl) luteinizing hormone-releasing hormone (LHRH), 
2) luteinizing hormone (LH), 3} testosterone (T), 4}prolactin, 5) 
ACTH, and 6) adrenal androgens—A^-androstenedione andde-
hydroepiandrosterone (DHEA and DHEA sulfate). Intracellu-
lar-mediated androgen action is shown hy the various symbols 
depicted within the prostate cell. These include T conversion to 
dihydrotestosterone (DHT) by 5a-reductase. 7) conversion of 
adrenal androgens, A^-androstenedione and DHEA to DHT, 8) 
binding of DHT derived from T and adrenal androgens to re-
ceptor to form the DHT-receptor complex, and 9) translocation 
of DHT-receptor complexes to nucleus and binding to acceptor 
site; 10) new protein synthesis is shown by M-RNA and prostate 
acid phosphatase (PAP), prostatic specific protein (PSP). 5a-
reductase, and so forth. (Erom Geiler J. Megestrol acetate plus 
low-dose estrogen in the management of advanced prostate car-
cinoma. Urol Clin North Am 1991 ;18:83-91. Reprinted with 
permission.) 
minimally androgen-dependent clones do prevail, stimulation 
by adrenal androgens could be supporting cellular growth. 
Labrie and Veilleux (10) showed varying degrees of androgen 
sensitivity in the Shionogi mouse model of prostate carcinoma 
(Fig 2). Geiler and associates (11) also demonstrated that while 
castration reduced the level of serum testosterone > 95%, intra-
cellular dihydrotestosterone decreased by only approximately 
60%. These data suggest that adrenal androgens have a more im-
portant role than was postulated by earlier investigators. 
Based on the above studies, and because all eariier studies on 
the effect of ablating adrenal androgens were performed after 
primary testicular ablation had failed, Labrie recommended that 
primary treatment of advanced prostate cancer include simulta-
neous ablation of both testicular and adrenal androgens. It was 
believed that such treatment would eradicate all clones of cells, 
even with varying androgen sensitivity. This theory was not 
widely accepted by the urologic community because much data 
existed, both animal and human, which showed no benefit from 
combined androgen ablation. At least two animal studies utiliz-
ing rat Dunning prostate cancer models should be cited; 1) cas-
tration alone versus castration plus cyproterone acetate (an an-
tiandrogen), and 2) LHRH agonist alone versus an LHRH ag-
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Fig 2—Response of four clones of cells to differing DHT levels 
in Shionogi mouse mammary tumor. (From Labrie F, Veilleux 
R. A wide range of sensitivities to androgens develops in cloned 
Shionogi mouse mammary tumor cells. Prostate 1986;8;293-
300. Reprinted with permission.) 
onist plus flutamide. No change in tumor weight was observed 
either with the monotherapy androgen ablation or with the com-
bination therapies (12,13). A few small clinical trials (fewer 
than 20 patients in each arm) have evaluated the possible benefit 
of complete androgen blockade, tn these .studies the rate of pro-
gression one year after castration was the same in patients re-
ceiving an LHRH agonist, an antiandrogen, or no adjuvant ther-
apy at all (7). 
Nonetheless, Labrie et al (14-16) also conducted clinical tri-
als and claimed impressive results. These data and public pres-
sure led the National Cancer Institute (NCI) to begin a large 
multicenter intergroup study of combined therapy enlisting the 
efforts of the National Prostate Cancer Project, Southwest On-
cology Group, Northem Califomia Oncology Group, Mid At-
lantic Oncology Program, and the North Central Cancer Treat-
ment Group (17). A total of 617 patients with newly diagnosed 
stage D2 adenocarcinoma of the prostate were randomized in a 
double-blind fashion to receive either an LHRH agonist (leu-
prolide) plus placebo, or leuprolide plus the antiandrogen flu-
tamide. There were 306 patients randomized to placebo and 311 
to flutamide. Three patients in each arm were randomized to re-
ceive no treatment. Evaluable patients included 272 from the 
placebo arm and 282 from the flutamide arm. Endpoints of the 
study were response, time to first evidence of failure, and sur-
vival. Patients were evaluated every three months by bone scan, 
serum acid phosphatase level, and performance status. Progres-
sion was defined as objective evidence of new disease in bone or 
soft tissue or a measurable increase in old disease. Patients were 
stratified by extent of disease and performance status; minimal 
disease included those with axial, skeletal, and pelvic involve-
ment only; extensive disease included patients with long bone, 
skull, rib, or visceral/soft tissue (lung) metastases. 
The results demonstrated a significant improvement in pro-
gression-free survival (16,5 versus 13,9 months) as well as in ul-
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Fig 3—National Cancer Institute Intergroup Protocol 0036; 
Survival classified by stratification and randomized treatment 
(December 1990). (Crawford ED, Eisenberg MA, McLeod DG, 
et al. A controlled trial of leuprolide with and without flutamide 
in prostatic carcinoma. N Engl J Med 1989;321 ;419-24. Re-
printed with permission.) 
Fig 4—National Cancer Institute Intergroup Protocol 0036: 
Progression-free survival classified by stratification and ran-
domized treatment (December 1990). (Crawford ED, Eisenberg 
MA, McLeod DG, etal. A controlled trial of leuprolide with and 
without flutamide in prostatic carcinoma. N Engl J Med 1989; 
321 ;419-24. Reprinted with permission.) 
timate survival (35.6 versus 28.3 months) for the flutamide 
group (Figs 3 and 4) (P value for each evaluation < 0.01). Al-
though they are statistically significant, the results have been 
considered to be cHnically insignificant by the medical commu-
nity. However, the results do indicate that, in the good perfor-
mance status, minimal disease group, combination therapy was 
associated with dramatically improved results compared to the 
group receiving placebo. At 60 months the median progression-
free survival had not been reached in the flutamide group, but 
was onty 19.1 months in the placebo group. Median survival 
was 39.6 months for the placebo group, but, at 60 months, had 
not yet been determined for flutamide tteated patients. Although 
the number at risk is small, these results wanant further investi-
gation. 
Other randomized trials of maximal androgen ablation have 
been carried out in Canada and Europe. All the studies have 
problems with design and endpoint evaluation, and therefore are 
not comparable to the NCI study. The Intemational Prostate 
Study Group, with 568 patients randomized, is the only other 
large study (18). Unfortunately, patients with locally advanced 
disease but without metastatic disease were included. A total of 
65% of the patients did have metastatic disease. The patients 
were randomized in an unblinded fashion to receive either the 
LHRH agonist zoladex alone or zoladex plus flutamide. The 
preliminary results, presented only in abstract form, show no 
statistically significant difference in objective response rate or 
in time to progression, at a median follow-up of 30 weeks. The 
report does not state how many patients were followed, how 
many were excluded, or for what reasons. 
The Canadian study compared patients after bilateral orchiec-
tomy who received the antiandrogen nilutamide to patients after 
orchiectomy who received placebo (19). There were 97 evalu-
able patients who received antiandrogen and 96 who received 
the placebo. The results showed an 87% response for the nilu-
tamide group and 61 % for the control group (P = 0.013). Median 
time to progression was 11.7 months for the placebo group and 
12.4 months for the nilutamide group, not a statistically signifi-
cant difference. Similarly, the 5.4-month survival advantage 
(24.3 versus 18.9) for the group receiving nilutamide was not 
significant. The study was designed to evaluate best response, 
not progression or survival. To evaluate all of these parameters, 
the study would have to include at least three times as many sub-
jects (20). 
tn France, Brisset et al (21) conducted a randomized, prospec-
tive, blinded trial comparing orchiectomy and placebo versus 
orchiectomy and anandron 150 mg daily or orchiectomy and an-
andron 300 mg daily. Patients were evaluated for best response, 
progression-free survival, and ultimate survival. A total of 160 
patients were studied in the three groups. Thirty-three patients 
were not evaluable because they were shown to have had no me-
tastasis on entry, had been lost to follow-up, or had medications 
beginning later than three months after orchiectomy. Of the 127 
patients for evaluation, 43 were in the placebo group, 46 in the 
150 mg anandron group, and 38 in the 300 mg anandron group. 
The objective response rate was 61% in each of the two anan-
dron-treated groups, compared to 33% in the placebo group. 
This is stated to be statistically significant, but a P value is not 
given. Progression-free survival and ultimate survival were sim-
ilar in all three groups. Median time to progression was 13 
months in all groups, and the median time to death was 22 to 24 
months in all three. The number of patients involved in this 
three-arm study is small, enough to evaluate response but not 
nearly enough to evaluate progression and/or survival. 
The European Organization of Research and Treatment of 
Cancer (EORTC) conducted a clinical trial comparing orchiec-
tomy versus orchiectomy plus cytoproterone acetate versus 1 
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mg/day of diethylstilbestrol (DES) (22). This was an unblinded, 
prospective randomized study. A total of 350 patients were en-
tered from 16 European institutions. Eleven patients were deter-
mined to be ineligible and six were removed from the study be-
cause of treatment toxicity. Four ofthese six had received DES 
and developed cardiovascular disease. Preliminary evaluation 
of 241 patients showed no difference in time to progression or in 
length of survival for any of the three methods of treatment. Best 
response to therapy was not reported, but the data appear to sup-
port the contention that there is no benefit from such combined 
androgen ablation. As with other evaluations, the EORTC study 
is not large enough to reveal the desired endpoints in a statisti-
cally significant manner. 
The EORTC is cunently engaged in an unblinded random-
ized trial of orchiectomy versus flutamide plus the LHRH ag-
onist zoladex (23). A total of 149 patients have been entered in 
the combination arm and 148 in the orchiectomy arm. Best re-
sponse, measured by bone scan, was 67% for orchiectomy and 
79% for combination therapy. Median time of progression was 
18 months for the orchiectomy group and 26 months for the 
combined therapy group (P = 0.03). In time to death, both 
groups were es.sentially the same with a median of approxi-
mately 30 months. This study may be criticized for a number of 
reasons. First and most important is that the investigators are not 
comparing similar groups but two entirely different treatments. 
Although there is suggestive indirect evidence, there is no direct 
data showing equivalent effects from orchiectomy and the ad-
ministration of LHRH agonists. Comparing this combination 
therapy to orchiectomy is not meaningful. Furthermore, this 
study, while large enough to evaluate best response, is also too 
small to evaluate progression and survival statistically. 
This compendium of apparently conflicting data demon-
strates the difficulty of deriving meaningful conclusions. Evi-
dence suggests a more favorable response to maximal androgen 
ablation and, for patients with "minimal" disease, the chance of 
improved progression-free survival as well as ultimate survival. 
However, too few patients have been evaluated to provide statis-
tical significance to the results of various treatment regimens. 
Cunentiy the NCI is sponsoring another double-blinded inter-
group trial comparing orchiectomy plus flutamide to orchiec-
tomy plus placebo to see if the favorable results of the first trial 
can be reproduced. This study will involve over 1,200 patients, 
which should provide enough patients in each group to obtain 
significant results for all parameters. 
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